When not to wait for an appointment
- Seek emergency care immediately for sudden vision changes, unusual pain or pale, grey or dusky skin near the injection site, particularly during or shortly after an injection, or sudden facial drooping, speech difficulty or limb weakness. These can signal a vascular complication and should not be treated as an ordinary lump.
- Get medical assessment that day for spreading redness, heat, worsening swelling and pain, pus or fever. Infection or inflammation needs assessment. Confusion, faintness or rapid breathing alongside these symptoms warrants emergency care.
Do not wait for the original clinic to answer a message or for complete records if symptoms are severe. These warnings draw on the Radiesse (+) safety label and NHS infection guidance; they are not an exhaustive emergency checklist.
Early swelling and delayed lumps are different patterns
Near the treatment date: swelling, bruising and tenderness can occur and often improve. That does not make every early lump harmless. Contact your clinician if symptoms worsen or differ from the recovery advice you received.
A persistent or later lump: it may be felt without being visible, and may or may not be painful or red. Sculptra’s label describes delayed bumps and nodules appearing days to months after treatment. Being painless does not establish that a lump is harmless or will resolve on its own.
“Lump” describes what you notice. It does not automatically mean a granuloma, a particular inflammatory reaction. The clinician needs the product history and an examination before identifying the cause. See the Sculptra label and FDA filler safety information.
Why the exact product matters
Biostimulator is a category, not a single material. Sculptra contains PLLA; some Juvelook formulations combine PDLLA and hyaluronic acid (HA); Radiesse (+) contains CaHA in a carrier gel with lidocaine. Product versions matter, so “collagen injection” is not enough detail for an assessment.
If you were treated overseas, request the original treatment record and product-label photographs. Keep the exact brand and version rather than translating everything as “filler.” Missing records should not delay necessary care.
Can the lump be dissolved like HA filler?
Not all materials can be managed in the same way. Hyaluronidase breaks down HA; it is not a direct dissolving agent for PLLA, PDLLA or CaHA. Having HA in a combined product does not mean its other components, or the entire lump, can be dissolved.
The FDA describes no specific reversal agent for PLLA or CaHA comparable to that used for HA. Management depends on the material and the cause of the lump, carries its own risks and cannot guarantee restoration of the original appearance. The HA filler dissolving guide explains that separate topic.
Do not start massaging, squeezing, puncturing or using medicines or injections to treat a new lump yourself. Routine aftercare instructions are not a treatment plan for a delayed complication.
What can examination and ultrasound establish?
The clinician will compare the lump’s location with previous treatment sites, examine the overlying skin and review whether it started immediately, persisted or returned after settling. Softness or hardness alone cannot confirm normal collagen formation, a product deposit or infection. It also cannot establish that an injection error occurred.
Ultrasound may help locate and characterise material beneath the skin in selected cases. A retrospective study of 62 patients referred with filler nodules described different imaging patterns, including those associated with PDLLA. It does not establish that ultrasound identifies every cause with certainty or replaces clinical assessment. Further investigation depends on the findings; there is no universal testing checklist for every lump. (Study of ultrasound patterns in filler nodules)
Will it go away, and how long might it take?
The brand name and time of onset alone cannot predict resolution. Sculptra’s patient information describes lumps that resolve spontaneously, others requiring treatment and some requiring surgery. That is not a reason to wait without assessment, nor a forecast for every biostimulator. (Sculptra patient information)
If observation is advised, agree a review date, what the clinician is monitoring and which changes mean you should return sooner, such as enlargement or increasing redness and pain. Before further cosmetic treatment in that area, tell the clinician that a lump is still being assessed.
Bring a short timeline and your records
- Treatment dates, exact product/version, batch number, amounts and treated areas from the record, if available.
- When the lump first appeared, whether it is changing, and any pain, redness, heat, fever or visual symptoms.
- Dated photographs before treatment, afterwards and when symptoms began.
- Previous injectables or procedures in the same area and any attempted treatment of the lump.
- Medical conditions, medicines, allergies and recent illness or dental work. These are context for assessment, not proof of what caused the lump.
Arrange assessment and follow-up in Thailand
Ask what possible causes still need to be considered, whether further tests or referral are necessary, and when to return if observation is advised. Clarify which changes require earlier review and the realistic goal and risks of any proposed management.
If you are travelling or moving between countries, tell the clinician when you leave and agree how follow-up will continue. Confirm language support and the facility’s experience with injectable complications before booking; neither should be assumed from an English website.
Contact the treating clinic for records and assessment, or ask for referral if it cannot assess the complication. The biostimulator overview provides product background; it does not establish availability of every complication-management service.